CytoDyn Updates

01/13/2022

https://www.cytodyn.com/newsroom/press-releases/detail/595/cytodyn-cancels-webcast-and-live-qa-scheduled-for-today

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

01/12/2022

https://www.cytodyn.com/newsroom/press-releases/detail/594/cytodyn-to-hold-webcast-and-live-qa-on-january-13

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

01/12/2022

https://www.cytodyn.com/newsroom/press-releases/detail/593/published-paper-indicates-leronlimab-shows-activity-against

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

01/06/2022

https://youtu.be/GmpJ639gjnk

CytoDyn Inc CEO Nader Pourhassan talks to Proactive about results from the 350 mg weekly dose of its Phase 2 NASH clinical trial. The Vancouver, British Colu...

01/05/2022

https://www.cytodyn.com/newsroom/press-releases/detail/592/leronlimab-14-week-nash-clinical-trial-met-primary

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

12/22/2021

https://www.cytodyn.com/newsroom/press-releases/detail/591/cytodyn-announces-favorable-ruling-granting-injunction

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

12/22/2021

https://www.cytodyn.com/newsroom/press-releases/detail/590/cytodyn-receives-positive-response-from-fda-in-regard-to

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

12/15/2021

https://youtu.be/jEZ8BlE6jxA

12/13/2021

https://www.cytodyn.com/newsroom/press-releases/detail/589/nash-phase-2-trial-open-label-portion-demonstrates-average

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

12/13/2021

https://www.cytodyn.com/newsroom/press-releases/detail/588/cytodyn-to-hold-webcast-and-live-qa-on-december-14

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…

12/13/2021

https://www.youtube.com/watch?v=tSnmdAy0yig&t=4s

CytoDyn Inc. CEO Nader Pourhassan tells Proactive its contract research organization in Brazil has met with the Brazilian Health Regulatory Agency and receiv...

12/09/2021

https://www.cytodyn.com/newsroom/press-releases/detail/587/cytodyn-submits-protocol-with-the-fda-for-phase-3

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor.  CCR5 appears to play…